Genedx Holdings Corp. (WGS) Stock Price & Analysis

Genedx Holdings Corp. (WGS) fell 0.14% to USD 85.87 as of September 9, 2026 at 01:07 UTC, according to Nexqual real-time market data.

WGS last closed at USD 85.87; the session ranged USD 83.02–86.53 on volume of 426,356 shares. Market capitalization is —, with a 52-week range of USD 32.21–170.87 (NMS). Source: Nexqual, September 9, 2026 at 01:07 UTC.

Key Statistics (as of September 9, 2026 at 01:07 UTC)

Technical Analysis (WGS)

Nexqual's technical model rates WGS "STRONG BUY" based on 5 bullish and 0 bearish signals across 126 daily candles, as of September 9, 2026 at 01:07 UTC.

Leadership (WGS)

Genedx Holdings Corp. is led by Katherine A. Stueland (age 49), CEO & Director, per Nexqual as of September 9, 2026 at 01:07 UTC.

Major Backers & Investors (WGS)

Notable institutional backers of Genedx Holdings Corp. include Corvex Management LP, Casdin Capital, LLC, ARK Invest, according to Nexqual as of September 9, 2026 at 01:07 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, September 9, 2026 at 01:07 UTC.

From Genedx Holdings Corp.'s Latest SEC 10-K Filing (filed 2026-02-23)

Key Strengths & Strategy (as disclosed to the SEC)

• GeneDx combines clinical expertise, advanced technology, and the proprietary GeneDx Infinity™ dataset to power the ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device Designation – enabling clinicians to deliver precise, fast, and actionable diagnoses.
• To achieve these objectives, we: • Deploy our team of approximately 120 field-based sales representatives and medical science liaisons, and construct an industry-leading brand, product, marketing, communications and market access platform that leverages our expertise, rich data, and decades of earned trust across the genetics community. • Partner with leaders across health systems, manufacturers, commercial and governmental payors and advocacy groups.
• Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, these steps may be circumvented, or third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology.
• We are also applying AI tools – like our machine learning powered gene ranker, Multiscore – on top of GeneDx Infinity TM to harness the power of our data, scale our platform and increase speed and turnaround time.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 01:07 UTC. This page is informational and not investment advice.